GURUFOCUS.COM » STOCK LIST » Real Estate » Real Estate » Lushang Freda Pharmaceutical Co Ltd (SHSE:600223) » Definitions » 3-Year RORE %

Lushang Freda Pharmaceutical Co (SHSE:600223) 3-Year RORE % : -27.54% (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Lushang Freda Pharmaceutical Co 3-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Lushang Freda Pharmaceutical Co's 3-Year RORE % for the quarter that ended in Mar. 2024 was -27.54%.

The industry rank for Lushang Freda Pharmaceutical Co's 3-Year RORE % or its related term are showing as below:

SHSE:600223's 3-Year RORE % is ranked worse than
67.07% of 1722 companies
in the Real Estate industry
Industry Median: 0.19 vs SHSE:600223: -27.54

Lushang Freda Pharmaceutical Co 3-Year RORE % Historical Data

The historical data trend for Lushang Freda Pharmaceutical Co's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lushang Freda Pharmaceutical Co 3-Year RORE % Chart

Lushang Freda Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.21 48.45 1.04 -101.69 -13.51

Lushang Freda Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -84.09 -120.37 -113.46 -13.51 -27.54

Competitive Comparison of Lushang Freda Pharmaceutical Co's 3-Year RORE %

For the Real Estate - Development subindustry, Lushang Freda Pharmaceutical Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lushang Freda Pharmaceutical Co's 3-Year RORE % Distribution in the Real Estate Industry

For the Real Estate industry and Real Estate sector, Lushang Freda Pharmaceutical Co's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Lushang Freda Pharmaceutical Co's 3-Year RORE % falls into.



Lushang Freda Pharmaceutical Co 3-Year RORE % Calculation

Lushang Freda Pharmaceutical Co's 3-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.23-0.325 )/( 0.655-0.31 )
=-0.095/0.345
=-27.54 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 3-year before.


Lushang Freda Pharmaceutical Co  (SHSE:600223) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Lushang Freda Pharmaceutical Co 3-Year RORE % Related Terms

Thank you for viewing the detailed overview of Lushang Freda Pharmaceutical Co's 3-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Lushang Freda Pharmaceutical Co (SHSE:600223) Business Description

Traded in Other Exchanges
N/A
Address
No. 9777 Jingshi Road, Building 5, Lixia District, Jinan City, CHN
Lushang Freda Pharmaceutical Co Ltd formerly Lushang Health Industry Development Co Ltd is a real estate developer in China. The company is engaged in the development of office buildings, infrastructure, apartments, and hotels.
Executives
Li Hang senior management
Yin Wei Directors, senior managers
Shao Zhao Wei senior management
Wang Zhong Wu senior management
Dong Hong Lin Director
Zhou Hong Bo senior management
Li Lu senior management
Liu Zeng Wei senior management
Zhang Quan Li senior management
Xu Tao senior management
Ju Hai Bo Director
Zhao Xi Liang Director
Pi Xi Cai Supervisors

Lushang Freda Pharmaceutical Co (SHSE:600223) Headlines

No Headlines